A microarray configuration to quantify expression levels and relative abundance of splice variants by Fehlbaum, Pascale et al.
A microarray configuration to quantify expression
levels and relative abundance of splice variants
Pascale Fehlbaum, Caroline Guihal, Laurent Bracco and Olivier Cochet*
ExonHit Therapeutics, 63/65 boulevard Mass e ena, 75013 Paris, France
Received December 23, 2004; Revised and Accepted February 17, 2005
ABSTRACT
Over the past decade, alternative RNA splicing has
raised a great interest appearing to be of high import-
ance in the generation of expression diversity. This
regulatory process plays a critical role in the normal
development and its impact on the initiation and
development of human disorders as well as on the
pharmacological properties of drugs is increasingly
being recognized. Only few studies describe specific
alternative splicing expression profiling. Microarray
strategieshavebeenconceivedtoaddressalternative
splicing events but with very few experimental data
related to their abilities to provide true quantification
values.Wehavedevelopedaspecificmicroarraycon-
figuration relying on a few, well optimized probes per
splice event. Basically, five probes of 24mer are used
to fully characterize a splice event. These probes are
of two types, exon probes and junction probes, and
are either specific to a splice event or not. The per-
formances of such a ‘splice array’ were validated on
synthetic model systems and on complex biological
materials. The results indicate that DNA chips based
on this design combining exon and junction derived
probes enable the detection and, absolute and relat-
ive quantification of splice variants. In addition, this
strategy is compatible with all the microarrays that
use oligonucleotide probes.
INTRODUCTION
The nearly complete coverage of the human genome indicates
that it encodes only 20000–25000 protein-coding genes (1).
This number is signiﬁcantly below the one estimated from
the complexity observed at the messenger RNA (mRNA)
level through analyses of expressed sequence tags (ESTs)
(between 100000 and 150000) (2,3). This ‘gene shortfall’
has raised a great interest in alternative RNA splicing,
a cellular mechanism generating different transcripts from a
single gene, which could account for this observed discrep-
ancy between the number of genes and mRNAs.
Large-scale bioinformatics analyses of alternative splicing
have reported high rates of alternative splicing, with over 60%
of all human genes expressing multiple mRNA (2,4) [see also
the following databases: EASED (5) (http://eased.bioinf.mdc-
berlin.de/statistics.html), ASD (6) (http://www.ebi.ac.uk./asd)
andPALS(7),(http://palsdb.ym.edu.tw)].Morerecently,large-
scale gene expression proﬁling experiments via microarrays or
SAGE surprisingly revealed an unexpected abundance of
expressed genomic sequences (8–10). In-depth analysis of
the transciptomes generated from human chromosomes 21
and 22 suggested that every human gene is likely to undergo
alternative RNA splicing (9). Thus, alternative RNA splicing
is a key element in providing functional diversity from the
global expression of the human genome.
Alterationsofthe splicingpatterns,bymutationordefectsat
the level of the spliceosome machinery, can lead to profound
cellular deregulations and cause human diseases (11,12).
Thus, 10% of point mutations resulting in inherited diseases
are disrupting splice site sequences (13) (see also the Human
Gene Mutation Database, http://archive.uwcm.ac.uk/uwcm/
mg/hgmd0). In addition, mutations in less well-deﬁned exonic
and intronic enhancers or suppressors of splicing also affect
splicing (14–16). It is now widely demonstrated that RNA
splicing can severely impact gene function. Compared with
its wild-type counterpart, a splice variant can exhibit different
enzymatic or signaling activities, novel subcellular localiza-
tion and altered protein stability [reviewed in (17)]. Antagon-
istic effects for isoforms produced by the same pre-mRNA
have also largely been described, most notably in the ﬁeld of
apoptosis (18,19).
Cis-o rtrans-acting mutations at the pre-mRNA level can
affect RNA splicing and also alter the ratio between the
expression levels of two isoforms. These ratios are thus critical
parameters that need to be quantiﬁed as some isoforms can
exert dominant negative or positive effects. Aggregation of
the microtubule-associated tau protein is associated with
several neurological disorders, including Alzheimer’s disease
and frontotemporal dementia and parkinsonism linked to
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doi:10.1093/nar/gni047chromosome 17 (FTDP-17). Tau exon 10 encodes one of the
four microtubule-binding sites. The correct balance between
tau isoforms is critical to neuronal survival. The normal ratio
between the isoforms with or without exon 10 is one. Some
FTDP-17 associated mutations occur within the exonic and
intronic regulatory sequences in and around exon 10 (20,21)
and have been shown to alter the ratio of the two tau isoforms
in in vitro models. It has also recently been shown that the
inclusion of exon 10 is higher in the affected brain regions
from Alzheimer’s patients (22,23). In addition, correction of
alternative splicing of tau exon 10 with antisense oligonuc-
leotides targeting splice junctions has been reported (24).
Another striking example of the critical importance of the
splice variants ratios lies within the two main determining
genes for spinal muscular atrophy (SMA), SMN1 and SMN2.
The SMN protein from the SMN1 gene was not expressed
in 95% of SMA patients owing to deletions in both alleles.
SMN2 is identical to SMN1 except for a single nucleotide
difference which attenuates the activity of an exonic enhancer
responsible for primarily producing an SMN2 mRNA lacking
exon 7. This transcript gets translated into a less or non-
functional SMN protein. There is a correlation between the
level of full-length SMN protein produced from the SMN2
gene and the severity of SMA as well as duration of the sur-
vival (25,26). Redirecting the balance from the exon 7 skipped
formtowardsthefull-lengthhasbeendemonstratedwitholigo-
nucleotide based molecules and with small molecular weight
compounds (27–31).
Splice variants expression ratios could also provide better
diagnostic or prognostic markers than the absolute levels of
either variant as it has recently been shown in the association
between acetylcholine esterase splice variants and treatment
outcome for Alzheimer’s disease patients (32). Thus, monit-
oring the speciﬁc level of absolute or relative expression of
splice variants could certainly help better deﬁne physiological
and pathological mechanisms.
The quantiﬁcation of splice variants requires discriminating
approaches that will take into account the presence of speciﬁc
sequences within the isoforms. The expression value must be
speciﬁc to the splice variant and associated isoforms should
not interfere with this value. Insertional events such as intron
retention, novel alternative exons, or certain uses of 50 or 30
cryptic sites will generate additional sequence information as
compared with a wild-type form. Such sequences could serve
as the basis for oligonucleotide design as probes for micro-
arrays or as PCR primers. On the contrary, deletion events
caused by exon skipping events or by certain uses of cryptic
splice sites do not generate such novel sequences. In this case,
one can only rely on novel junction sequences to discriminate
from the wild-type counterpart. The design of oligonucleotide
primers that span junction sequences for isoform-speciﬁc PCR
ampliﬁcation has been described previously (33–36). The
reaction conditions of such PCR assays have to be carefully
optimized to avoid contaminating signals due to mispriming.
Splice junctions speciﬁc probes have also been used in the
design of an RNA invasive cleavage assay to monitor the
expression of FGFR2 splice variants (37). RASL (RNA-
mediated annealing, selection and ligation) has also been
applied to the study of splice variants (38). In this latter
approach, oligonucleotides that are complementary to
sequences located on both sides of a splice junction are ligated
to be PCR ampliﬁed. Fluorescent amplicons can then be
applied to microarray for detection. However, the scale-up
of these different platforms, i.e. their ability to study several
hundreds or thousands of splice events in parallel, is unclear at
this time.
DNA microarrays have become a widely used technology
for large-scale gene expression studies. Proﬁling alternative
splicing on such platforms has been described in a limited
number of studies (4,38–43). These studies describe the feas-
ibility to monitor splicing events on microarray platforms, but
quantiﬁcation methods for the absolute and relative levels of
expression of splice variants have not been extensively
developed.
The microarray conﬁguration described here provides an
efﬁcient splice variant detection platform offering the possib-
ility to measure expression levels using a limited number of
probes. A given splice event is represented by a set of ﬁve
probes speciﬁc for exonic sequences and for sequences
representing novel junctions being created or deleted by the
splicing event. The method is suitable for every type of spli-
cing events: exon skipping, cassette exons, intron retention
and alternative 50 or 30 cryptic sites. In addition, the balance
between different isoforms can be determined using the
expression values generated by this speciﬁc set of probes.
This conﬁguration is compatible with any microarray that
uses oligonucleotide probes.
In this study, a splice array was built with a series of probes
designed to monitor the expression of 42 isoforms. The ability
of this platform to provide absolute and relative quantiﬁcation
of splice variants was evaluated in synthetic model systems
and in more complex biological settings.
MATERIALS AND METHODS
Models for experimental validation
The following 18 genes with corresponding isoforms have
been selected for this study:
MCL1 (NM_021960), BIN1 (NM_004305), APP
(NM_000484), HSPC111 (NM_016391), APEX (NM_001641),
MYBL2 (NM_002466), FKBP1A (NM_00801), DUSP3
(NM_004090), PPIB (NM_00942), NUDC (NM_006600),
GSTZ1 (NM_001513), ROBO1 (NM_002941), EWSR1
(NM_005243), PRKDC (NM_006904), CDC37 (NM_007065),
MGC8721 (NM_016127), hnRNP-A/B (NM_031266) and
hnRNPD (NM_031370) (see Supplementary Table S1: listing
of the splice events).
For every gene, a pair of primers was designed to PCR
amplify a long and a short isoform in the region where the
splice event takes place. PCR was done on breast cell line
material. All PCR fragments were cloned into pGEM
R-T
Vector (Promega) or TOPO
TM Vector (Invitrogen) and valid-
ated by sequencing.
Biological samples
Human breast cell lines MCF7 (ATCC HTB-22), MDA-MB-
435 (ATCC HTB-129), T47D (ATCC HTB-133) and BT549
(ATCC HTB-122) obtained from ATCC were maintained
following the supplier’s recommendations. Total RNA was
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turer’s suggested protocol.
Human brain total RNA (ref. 7962) was purchased from
Ambion. Total RNA from human metastatic melanoma tissue
sample was kindly provided by the Dermatology Department,
University of Geneva. RNA from patient’s cutaneous back
metastasis tissue (stage III, nodular malignant melanoma)
was extracted using caesium chloride method. All RNA
preparations were quality controlled for integrity, using the
Agilent Bioanalyser 2100 (Agilent Technologies).
Parameters for probe design
Probes were designed with homogeneous melting temperature
and similar lengths to obtain a common thermodynamic pro-
ﬁle. For this pilot study, we applied the following selection
criteria using Array Designer 2 (Premier Biosoft): (i) %GC:
40–60% for 24 and 30mer, 30–60% for 40mer; (ii) melting
temperature: 65 – 3 C for 24mer, 69 – 4 C for 30mer and
72 – 4 C for 40mer; (iii) primer concentration, 50 nM; and
(iv) salt concentration, 50 mM. Finally, oligonucleotides with
signiﬁcant hairpin tendencies (DG >  7 kcal/mol), self-
dimerization tendencies (DG >  4 kcal/mol) or presenting
more than six identical bases in a row were discarded. Junction
probeswere preferably centeredonthesplice site(12–12 bases
for a 24mer) but other combinations were also designed for
performance study (10–14, 11–13, 13–11 and 14–10 bases).
To avoid cross-hybridization, speciﬁcity of each probe was
evaluated by BLAST analyses against the human EST data-
bases using parameters forshort,nearly exact matches(Expec-
tedvalue=1000,wordsize=7andpenaltyformismatch= 1).
Finally, a total of 121 oligonucleotide probes were designed to
detect and quantify 42 isoforms. In addition, 24mer control
probes targeting exons of Arabidopsis thaliana mRNA for
photosystem I chlorophyllA/B-binding protein (X56062)
and A.thaliana lipid transfer (AF159801) were designed to
serve as exogenous controls.
Splice-array preparation
The 24, 30 and 40mer oligonucleotides modiﬁed with a
50-amine-(CH)5-modiﬁcation for covalent immobilization
were printed on three distinct CodeLink
TM (Amersham
Biosciences) glass slides according to their length, using
the Microgrid II Arrayer (Genomic Solution). Desalted probes
were broughttoaﬁnalconcentration of25nmol/mlin150mM
sodium phosphate, pH 8.5 before printing on the slides. Each
oligonucleotide was spotted eight times per array. Residual
reactive groups were blocked with a solution of 0.1 M Tris,
50 mM ethanolamine, pH 9.0 and 0.1% SDS, rinsed with water
and washed with 4· SSC/0.1% SDS.
Target preparation and labeling
For synthetic model systems, labeled targets were prepared
from pairs of cDNA clones, each representing a wild-type
form and a splice variant [also called : long form
(LF) + short form (SF)]. About 2 mg of corresponding
cRNA was generated using in vitro transcription systems
(T7 or SP6 Megascript kit; Ambion).
For breast cell lines, brain and melanoma RNAs, labeling
was performed using a standard ampliﬁcation protocol.
Brieﬂy, 5 mg of total RNA were reverse transcribed in 20 ml
with 200 U Superscript II (Life Technologies) and 1 mg
Oligo(dT)24-T7 [50-GGCCAGTGAATTGTAATACGACT-
CACTATAGGGAGGCGG-(dT)24-30]i n1 · ﬁrst-strand
buffer (Life Technologies) at 42 C. Total RNA was spiked
with 300 pg of A.thaliana Cab mRNA (Stratagene) for
calibration purposes. Second-strand synthesis (SSS) was
carried out in 150 ml ﬁnal volume containing 40 U DNA
polymerase I, 2 U of Escherichia coli RNase H, and 10 U
of E.coli DNA ligase in 1· second-strand buffer (Life Tech-
nologies) by adding 130 ml of ice-cold SSS premix to the 20 ml
RT reaction and incubated at 16 C for 2 h. The double-strand
DNA synthesis was terminated by adding 10 U of T4 DNA
polymerase and incubating for 10 min at 16 C. cDNA
was puriﬁed with phenol/chloroform/isoamyl-alcohol
25:24:1 (v/v/v) extraction on Phase lock gels (Eppendorf)
and precipitated overnight at  20 C with 7.5 M NH4Ac
and absolute ethanol.
TranscriptionofdsDNAwaspreparedin20mlat37  Cfor3h
using MEGAscript T7 Transcription kit (Ambion) (7.5 mM
ATP, 7.5 mM CTP, 7.5 mM GTP, 3.75 mM UTP and 3.75 mM
aaUTP). Ampliﬁed RNA was puriﬁed on RNeasy mini col-
umns (Qiagen) according to the manufacturer’s protocol.
cRNA was quantiﬁed by absorbance at 260 nm, and quality
controlled with the Agilent RNA Bioanalyser 2100. For bio-
logical material, up to 10 mg of amino-allyl-cRNA (aa-cRNA)
sample were labeled using Cy5 or Cy3 (Amersham Bio-
sciences) in 50% (v/v) dimethyl sulfoxide and 0.1 M
NaHCO3, pH 9.0 for at least 1 h at room temperature. For
aa-cRNA derived from cDNA clones, a mixture of each vari-
ant was prepared using 1 mg per gene as starting material for
the labeling reaction as described above. The reaction was
completed by adding 4 ml of hydroxylamine 4 M as a quench-
ing reagent, and targets were puriﬁed with two washes on a
Microcon-30 (Millipore). The puriﬁed labeledaa-cRNAs were
fragmented in 1· fragmentation buffer (200 mM Tris-acetate,
100 mM KOAc and 80 mM MgOAc) at 94 C for 35 min and
puriﬁed on a Microcon-10 (Millipore). For the spiking experi-
ments, 2 mg Drosophila melanogaster cRNA were added to
the target as a carrier during fragmentation to create a complex
background. Labeled Drosophila cRNA was used in prelim-
inary experiments and no cross-hybridization signal was
detected. Therefore, further hybridizations were done with
unlabeled Drosophila cRNA.
Hybridization conditions
Either 7–10 mg of fragmented biological material cRNA or
2 mgo fDrosophila cRNA spiked with different isoform
RNAs at various concentrations were denatured in 15 mlo f
0.1mg/mlsalmon sperm DNA,5·SSCbufferwith 0.1%(w/v)
SDS for 3 min at 95 C and hybridized on the splice array.
Unless mentioned in the text, slides were incubated for 16 h in
a5 5  C hybridization oven. Washes were performed twice for
5 min in 2· SSC, 0.1% (w/v) SDS at hybridization temper-
ature, then for 1 min in 0.2· SSC and for 1 min in 0.1· SSC
at room temperature. Slides were ﬁnally spin-dried before
reading.
Splice-array analysis
The splice arrays were scanned with a ScanArray 4000
(Packard-Bioscience). For quantiﬁcation studies using
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the ﬂuorescent intensity values of the common exon probe
(Ex1, see Figure 1) after hybridization with a mixture
containing 50% LF labeled with Cy5 and 50% SF labeled
with Cy3. For biological material analysis, the calibration
required oligonucleotides speciﬁc to A.thaliana Cab. Scanned
microarray images were analyzed using the QuantArray Ana-
lysis Software (Packard-Bioscience) and reports were impor-
ted into GeneTrafﬁc Duo data management and analysis
software (Iobion Informatics) along with TIFF images.
Local background intensities, calculated for each feature
by QuantArray, were subtracted prior to normalization by
GeneTrafﬁc. All probes with raw intensities less than twice
the average local background were discarded from the ana-
lysis. For spiking experiments, intensities were not further
normalized. Hybridizations with biological material were
normalized using the global intensity method included in
the microarray analysis software. The ratios of normalized
ﬂuorescent intensities for each feature were used for sub-
sequent analysis.
RESULTS
The splice-array design
The splice array is based on the design of probes located on
conserved exons, alternative exons as well as on the constitu-
tive and alternative splice junctions. The different types of
splice events (exon skipping, novel exon, internal exon dele-
tion, intron retention or alternative usage of splice donor or
acceptor sites) are displayed in Figure 1. Each splice event is
associated with two isoforms called LF and SF. The wild-type
isoform can either be LF or SF depending upon the nature of
the splice event.
For a single splicing event, a set of ﬁve oligonucleotides is
designed: one probe is speciﬁc for one of the conserved exons
(not involved in the splice event) to measure the RNA amount
of the long and short forms. One probe designed in the addi-
tional exonic sequence that differentiates LF and SF and
two probes spanning the junctions ﬂanking this additional
sequence are used to monitor the LF only. The detection of
the short isoform relies on a single junction probe. Note that,
theoretically, only one of the three LF-speciﬁc probes could be
used to detect and quantify the long isoform.
Probe thermodynamics (length, Tm, %GC and secondary
structure) were carefully controlled to fall in a range as narrow
as possible (see Material and Methods: parameters for
probe design). The speciﬁcity of the probes was evaluated
by BLAST analyses of the oligonucleotide probes against
the human EST databases to avoid cross-reactivity issues.
Influence of probe length and validation of
probe specificity
Speciﬁcity studies were ﬁrst carried out by evaluating three
different probe lengths (24, 30 and 40mer). We restricted our
analysis to short oligonucleotides to avoid the potential
hybridization of half of the junction probe to a single exon.
Independent slides prepared with probes of 24, 30 or 40mer
(Figure 2A and B for probe location and sequence) were
hybridized at 55, 60 and 65 C, respectively, to increase the
stringency and the hybridization speciﬁcity. MCG8721 wild-
type and isoform targets mixed as an equimolar ratio were
hybridized in parallel to the three slides.
The long isoform cRNA was readily detected by the 40mer
Jct1-3 oligonucleotide (Figure 2C and D), which should only
hybridize to the short isoform junction. Conversely, the short
isoform cRNA was detected by the 40mer Jct1-2 and Jct2-3
oligonucleotides, which should only hybridize to the long
isoform. The 30mer junction probes also showed a similar
behavior, although less pronounced. Only the 24mer provided
thespeciﬁcityrequiredforisoform-speciﬁcdetectionofaltern-
atively spliced events. Similar results have been obtained with
two other genes (data not shown).
For the subsequent validation steps, we prepared a splice
array gathering 121 probes (24mer) designed on 42 isoforms
from a set of 18 selected genes. Each probe was spotted in
eight replicates. The ﬁnal density per array was 1176 oligo-
nucleotides including exogenous controls. The validation of
the speciﬁcity of the 24mer probes was ﬁrst conﬁrmed with
cloned isoforms for four different genes in a complex RNA
setting. The long isoforms were labeled with Cy3 and the short
isoforms with Cy5. In parallel, D.melanogaster total RNA was
Figure1.Alternativesplicingeventsandprobelocationforsplice-arraydesign.
Oneoligonucleotideisspecificfortheskippedexonortheintronretention(Ex2
or Ex10) in the spliced isoform and enables the quantification of the long form
(LF). One oligonucleotide is specific for the sequence in one of the adjacent
exons (Ex1) not involved in the splice and will measure the amount of the LF
plus the short isoforms (SF). Different oligonucleotides monitor the different
junctions:J1-2,J2-3andJ1-3(A),J1-10,J1 0-2(B),J1-10,J1 0-2andJ1-2(C);two
junction probes being LF specific, one junction probe being SF specific.
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the speciﬁcity of the hybridization, equal amounts of long and
short isoforms of a given gene were diluted in Drosophila
cRNA. As expected, more than 90% of the signal detected
for probes Ex2, J1-2 and J2-3 is due to the LF while this
isoform is responsible for <10% of the hybridization signal
on probe J1-3 (Figure 3).
Quantitative measurements of splice variants
We then performed experiments to simulate a biological sys-
tem in which a long and a short isoform from the same gene
are expressed, the expression of one isoform being altered in
one sample compared with a second sample. To this end, we
compared two artiﬁcial samples made by mixing various
molar ratios of cloned isoforms. The goal was to assess
whether we could retrieve the expected fold changes for
each isoform in the samples. The mixed isoforms were spiked
into Drosophila cRNA to generate two samples, A and B. Two
sets of experiments have been independently performed and
their results are compiled in Table 1. In the ﬁrst set of experi-
ments (Set 1), sample A contained 80% of long isoforms and
20% of short isoforms (w/w) and both LFs and SFs were
labeled with Cy3. Sample B was prepared with 40% long
isoforms and 60% short isoforms and both LFs and SFs
were labeled with Cy5. In the second set (Set 2), sample A
was made with 20% of LF and 80% of SF and sample B with
90% of LF and 10% of SF. Both samples from a given set were
co-hybridized on the 24mer splice array, using (i) equal
amounts of A and B, (ii) twice the amount of B and (iii) four
times the amount of B. Fluorescent hybridization signals were
read as described previously and raw data were imported into
the GeneTrafﬁc software (Iobion Informatics). We next
determined the fold changes (sample B over sample A) for
the different spiked genes in each set and for each A:B ratio.
Figure2.Probespecificity.(A)Locationofthefiveprobesdesignedtomonitortheskippingofexon2oftheMGC8721gene(longform,LF;shortformSF).(B)Probe
sequences[oligonucleotidesnamesaredefinedin(A)].Bracketsindicatethesequencelimitsforthe24,30and40mer.Thearrowsrefertothejunctionpositions.(C)
2.5ngoftheLFtranscriptwaslabeledwithCy3,and2.5ngoftheSFtranscriptwaslabeledwithCy5.Hybridizationtemperaturesforthe24,30and40merwere55,60
and 65 C, respectively. The overlays of the images are presented for the three probe lengths tested with four replicates for each probe. (D) The graph shows the
specificityofthehybridizationoftheLFonthe24,30and40merprobesaftermeasurementsandnormalizationofthefluorescenthybridizationsignalsderivedfrom
(C) in both channels. The percentage of binding of the LF is obtained by measuring the ratio of fluorescent Cy3 signal to the overall signal (Cy3 + Cy5).
Figure 3. Hybridization specificity. The specificity is expressed as a
percentage of hybridization of the long isoform with respect to the five
oligonucleotides characterizing the splice event. The long form (LF)
transcript was labeled with Cy3, the short form (SF) transcript with Cy5.
The fluorescent signals were measured in both channels and normalized.
The probes are indicated on the x-axis, the y-axis presents the percentage of
binding of the LF by determining the ratio of the fluorescent Cy3 signal to the
overall signal (Cy3 + Cy5). The results are presented for four different genes.
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the common exon (with probe Ex1 or Ex3), for the skipped
exon (with probe Ex2) and for the short isoform junction (with
probe J1-3), respectively. The results are presented in Table 1
(Fold changes section).
Theoretical fold changes were anticipated from the initial
amounts of LF and SF mixed together in samples A and B
(values reported in bold in Table 1). Experimental values
were calculated for LF and SF, LF solely and SF solely,
using probes Ex1 or Ex3 (speciﬁc for the common exon),
Ex2 (LF speciﬁc) and J1-3 (SF speciﬁc), respectively. The
experimental fold changes determined for the different
genes tested were found to be close to the expected values.
Expected fold changes from both sets of Table 1 when
plotted against observed values generated an R
2 determinant
coefﬁcient of 0.945. In set 2, we generated mixtures with
larger differences in the amounts of LF and SF to evaluate
the limits of the method. Even with ratios of 12 and 0.25, the
quantiﬁcation still provided acceptable results (Table 1).
A more signiﬁcant deviation from the expected values
was observed only for the extreme deregulations (0.125
and 18).
The relative abundance between the long and the short
isoforms of a given gene in both samples (A and B) can be
derived from the following calculation. The composition of
samples A and B can be translated into two equations, x being
Table 1. Fold changes and relative abundance of long and short isoforms
Ratio A:B Isoform Fold changes (B/A) Relative abundance
RE1 RE2 RJ Sample A (Reference) Sample B (Experimental)
LF + SF LF SF LF (80%)S F ( 20%)S D L F ( 40%)S F ( 60%)S D
Set 1
1:1 Theoretical fold
changes
1 0.5 3 Isoform
quantity (ng)
41 23
NM_031370 0.91 – 0.11 0.49 – 0.09 2.52 – 0.62 77.9 22.1 –4.6 41.4 58.6 –4.7
NM_005243 1.26 – 0.39 0.54 – 0.19 3.17 – 0.87 72.7 27.3 –0.7 30.5 69.5 –1.0
NM_001513 1.01 – 0.22 0.61 – 0,15 2.26 – 0.01 74.8 25.2 –7.0 44.5 55.5 –3.1
1:2 Theoretical fold
changes
21 6 Isoform
quantity (ng)
41 46
NM_031370 1.76 – 0.17 0.94 – 0.06 4.95 – 0.20 79.7 20.3 –1.9 42.9 57.1 –2.3
NM_005243 2.33 – 0.03 1.06 – 0.03 5.85 – 0.08 73.5 26.5 –1.5 33.4 66.6 –2.0
NM_001513 1.89 – 0.04 1.14 – 0.02 5.25 – 0.42 81.7 18.3 –1.3 49.2 50.8 –0.7
1:4 Theoretical fold
changes
421 2 Isoform
quantity (ng)
41 8 1 2
NM_031370 3.84 – 0.28 2.10 – 0.16 10.56 – 0.25 79.5 20.5 –1.2 43.5 56.5 –0.4
NM_005243 3.52 – 0.20 2.35 – 0.18 9.76 – 0.98 84.0 16.0 –1.4 56.1 43.9 –2.1
NM_001513 4.06 – 0.06 2.39 – 0.03 10.80 – 0.82 80.0 20.0 –1.6 47.0 53.0 –1.0
Sample A (Reference) Sample B (Experimental)
LF (20%)S F ( 80%)S D L F ( 90%)S F ( 10%)S D
Set 2
1:1 Theoretical fold
changes
1 4.5 0.125 Isoform
quantity (ng)
28 91
NM_005243 1.13 – 0.24 5.97 – 3.12 0.27 – 0.01 18.1 81.9 –5.7 79.5 20.5 –2.6
NM_001513 0.86 – 0.07 3.3 – 0.27 0.28 – 0.15 19.3 80.7 –0.3 74.7 25.3 –11.4
NM_000484 1.32 – 0.32 3.13 – 0.57 0.23 – 0.06 37.1 62.9 –2.4 89.1 10.9 –0.2
NM_000801 1.59 – 0.58 4.89 – 2.26 0.20 – 0.06 31.4 68.6 –3.6 91.2 8.8 –0.2
1:2 Theoretical fold
changes
2 9 0.25 Isoform
quantity (ng)
2 8 18 2
NM_005243 1.71 – 0.68 8.88 – 3.62 0.39 – 0.04 15.0 85.0 –1.1 77.8 22.2 –6.9
NM_001513 1.44 – 0.05 6.90 – 0.24 0.32 – 0.07 17.1 82.9 –0.7 81.9 18.1 –3.4
NM_000484 1.45 – 0.27 5.76 – 0.49 0.24 – 0.02 21.7 78.3 –2.8 86.8 13.2 –1.9
NM_000801 2.12 – 1.01 6.25 – 2.08 0.28 – 0.03 28.6 71.4 –6.5 88.1 11.9 –5.4
1:4 Theoretical fold
changes
4 18 0.5 Isoform
quantity (ng)
1 4 18 2
NM_005243 2.71 – 0.86 13.3 – 3.33 0.57 – 0.11 16.4 83.6 –1.7 81.7 18.3 –2.8
NM_001513 3.13 – 0.10 14.6 – 2.08 0.68 – 0.14 18.0 82.0 –2.8 82.3 17.7 –3.6
NM_000484 2.79 – 0.66 11.2 – 1.25 0.51 – 0.07 20.8 79.2 –3.2 85.0 15.0 –2.1
NM_000801 3.15 – 1.40 10.1 – 1.01 0.56 – 0.07 26.1 73.9 –11.3 83.9 16.1 –7.4
LongandshortisoformsfordifferentgenesweremixedtogetherinvariousquantitiestogenerateartificialsamplesAandB. Theexpectedfoldchangesandrelative
abundance(%)areindicatedinbold.Set1andSet2areindependentassayswithdifferentLFandSFratiosforsamplesAandB.Ineachset,threehybridizationswere
performed with different A:B ratios: (i) equal amount of A and B (1:1), (ii) twice the amount of B (1:2) and (iii) four times the amount of B (1:4). Fold changes and
relativeabundancevaluesarethemeanoftwoindependentexperimentsperformedbytwouserswiththecorrespondingstandarddeviation(SD)calculationsreported
next to values. See Supplementary Table S1 for the LF and SF definition for each transcript.
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short isoform. Then:
 xA þ yA ¼ 1
xB þ yB ¼ 1
 xB ¼ xA R RE2
yB ¼ yA R RJ
)
)
 
xA ¼ 1   yA
 R RE2ð1   yAÞþyA R RJ ¼ 1
) yA ¼
1  R RE2
 R RJ  R RE2
where
 R RE2 ¼
RE2
RE1
 R RJ ¼
RJ
RE1
The results obtained for the different spiked isoforms are
presented in Table 1 (Relative abundance section) with the
expected percentages of LF and SF indicated in bold. For all
the genes being evaluated, the experimental values are close
to the theoretical values across the hybridizations. Expected
relative abundance values from both sets of Table 1 when
plotted against observed values generated an R
2 determinant
coefﬁcient of 0.953. This experiment has been repeated for
bothsetson different batches ofsplice arraysbytwo userswith
similar results.
Potentially, three probes couldserve forthe characterization
of the longer isoform: Ex2, Jct1-2 and Jct2-3. Calculation
performed with the two junction probes, Jct1-2 and Jct2-3
led to similar results (data not shown). Therefore, for further
analysis on biological material, a mean value of the ratio
corresponding to the three probes (Ex2, Jct1-2 and Jct 2-3)
was used for relative abundance calculation.
Sensitivity studies
The accuracy and the sensitivity of the splice variant quanti-
ﬁcation method were then assessed with spiking experiments
using a mixture of six isoforms for the detection of three splice
events. Two dilutions of sample A (40% LF, 60% SF, Cy5
labeling) and sample B (80% LF, 20% SF, Cy3 labeling) have
been co-hybridized with always twice the amount of spiked
cRNA isoforms in sample B than in sample A. The fold
changes were determined with GeneTrafﬁc for the sets of
hybridizations. The calculation method described above was
next applied and the results obtained for different amounts
(1.25 and 0.08 ng per isoform in A) of material tested are
presented in Table 2.
The experimental values measured for the mixture contain-
ing 1.25 ng of sample A are close to the expected values.
Diluting the isoforms down to a concentration as low as
0.03 ng (3 pM or 1/10000 relative abundance) per isoform
for the sample A still provide acceptable results taking into
account potential errors in consecutive sample dilutions.
Although not tested on the different oligoarray platforms,
the sensitivity limit of splice variant quantiﬁcation is likely
to correspond to the sensitivity limit of a given platform.
Platform validation with biological material
Additional assays were performed to assess whether we could
detect and quantify known isoforms using biological material.
Labeled cRNA from MCF7 breast cell line was used as ref-
erence for co-hybridizations with cRNA from three other
breast cell lines: T47D, MDA435 and BT549. All the hybrid-
izations were repeated with dye swap before performing
differential expression and isoform relative abundance
calculations.
Four isoforms from four genes (out of the 18) were found
signiﬁcantly deregulated at least once in the three hybridiza-
tions (fold changes >1.80 or <0.55) (Table 3). Among these
genes, we further studied the skipping of exon 80 of PRKDC
corresponding to a splice event described in the literature (44)
(Figure 4A). The LF of PRKDC is overexpressed in MDA435
and T47D by 2-fold relative to MCF7. The relative abundance
calculations indicated that the exon skipped isoform was the
minor form in all cell lines, however, with a signiﬁcant differ-
ence between BT549 where it represented 23% and MDA435
or T47D where it only represented 4%. RT–PCR experiments
were performedtoamplifybothPRKDC isoforms (Figure4B).
The band intensities of the two isoforms were in agreement
with the microarray results. The long isoform appeared more
expressed in T47D and MDA435 than in MCF7 and the short
Table 2. Quantification of splice events between two situations for sensitivity determination
Amount of isoforms
in samples A:B
Isoform Fold changes (B/A) Relative abundance (%)
RE1 RE2 RJ Sample A (Reference) Sample B (Experimental)
LF + SF LF SF LF (40%) SF (60%) LF (80%) SF (20%)
1.25 : 2.5 Theoretical
fold changes
2 4 0.66 Isoform
quantity (ng)
0.5 0.75 2 0.5
NM_006904 1.75 4.06 0.74 30.4 69.6 70.5 29.5
NM_005243 1.89 5.43 0.45 28.9 71.1 83.1 16.9
NM_001513 1.77 3.03 0.56 48.9 51.1 83.9 16.1
0.08 : 0.16 Theoretical
fold changes
2 4 0.66 Isoform
quantity (ng)
0.03 0.05 0.12 0.03
NM_006904 1.61 2.57 0.71 48.3 51.7 77.2 22.8
NM_005243 1.34 2.64 0.59 36.5 63.5 72.1 27.9
NM_001513 1.65 2.16 1.2 46.8 53.2 61.4 38.6
Longforms(LFs)andshortforms(SFs)ofthreedifferentgeneshavebeenmixedtogetheratvariousproportions(40%LF,60%SFforA;80%LF,20%SFforB).In
eachcase,theamountofsampleBwastwicetheamountofsampleA.Theexpectedfoldchangesandrelativeabundance(%)arereportedinbold.Foldchangeshave
been measured and the resulting values were used in our calculation method to determine the relative abundance of the long and short isoforms for each gene.
PAGE 7 OF 11 Nucleic Acids Research, 2005, Vol. 33, No. 5 e47isoform was barely visible on the gel for T47D and MDA435
while it appeared more abundant in BT549.
In another set of experiments, cRNAs from melanoma and
brain tissues were co-hybridized in dye-swap assays. We
observed a signiﬁcant deregulation for three isoforms (fold
changes >1.80 or <0.55) (Table 4). Among those, APP is a
well-described alternatively spliced gene (42,45). The set of
APP spotted probes was designed to monitor the splice event
corresponding to the double skipping of exons 7 and 8 (APP
[ 7/8] or APP SF). It turns out that another isoform corres-
ponding to the skipping of exon 8 is also expressed in the
melanoma and brain tissues (APP [ 8]) (Figure 4C). The APP
probes enabled us to calculate the relative abundance of
APP SF with respect to the two longer isoforms (APP wt
and APP [ 8]). The exon 6 probe is located in an exon com-
mon to the three isoforms (wt, [-8] and [-7/8]). Exon 7 is
skipped in APP SF and the corresponding speciﬁc probe
(E7) allows the quantiﬁcation of the two longer isoforms
(wt and [ 8]). Probe Jct 6-9 is speciﬁc for APP SF.
In Table 4, a clear difference in the relative abundance
of APP SF was observed between melanoma and brain
samples. This is in agreement with the validation by
RT–PCR (Figure 4D) which showed a preponderance of the
two longer isoforms (APP wt and APP [ 8]) in melanoma
(84% versus 16% from the splice-array data) while the APP
[ 8] and APP [ 7/8] isoforms were roughly in equal amounts
in brain (57% versus 43% from the splice-array data). Our
results for APP are in agreement with a recent study using
another junction array platform, although no quantitative
measurements were reported (42).
It should also be noted that results from the E6 probe
located in the common exon (exon 6) demonstrated no signi-
ﬁcant deregulation of the APP messengers between brain and
melanoma (fold change = 1.39). Hence, by using single probes
(or probe sets) located in constitutive regions, one would have
concluded to the absence of gene deregulation, while isoform-
speciﬁc probes were able to detect and quantify a speciﬁc
deregulation of the splice variants.
Table 3. Fold changes and relative abundance for deregulated isoforms in MDA435, T47D or BT549 versus MCF7
Gene Isoforms Experimental sample Fold changes (Exp/MCF7) Relative abundance
LF + SF (RE1)L F ( RE2)S F ( RJ) Experimental sample
%L F %S F
FKBP1A Wild type (SF) MDA435 3.07 1.16 3.25 3.2 96.8
Intron 4 retention (LF) T47D 1.14 1.13 1.2 NA NA
BT549 1.58 0.98 1.73 12.4 87.6
GSTZ1 Wild type (LF) MDA435 0.62 0.58 1.21 87.6 12.4
Exon 5 skipping (SF) T47D 0.97 0.96 1.39 96.7 3.3
BT549 0.53 0.50 0.93 89.0 11.0
PRKDC Wild type (LF) MDA435 1.93 1.97 1.23 96.3 3.7
Exon 80 skipping (SF) T47D 2.19 2.22 1.66 95.9 4.1
BT549 1.56 1.60 1.45 76.8 23.2
MCL1 Wild type (LF) MDA435 0.91 0.53 1.08 17.8 82.2
Exon 2 skipping (SF) T47D 1.22 0.95 1.19 NA NA
BT549 1.28 1.87 0.96 51.3 48.7
Significantderegulationsarereportedinbold.RE2valuescorrespondtothemeanoffoldchangescalculatedwitheachLF-specificprobes(Ex2,J1-2andJ2-3).NA,not
applicable (see in text the limitations for the relative abundance determination).
Figure 4. IsoformstudyforPRKDCandAPPgenes.(AandC)Splicingeventsandprobelocationtomonitortheskippingofexon80fromPRKDCandexon7from
APP, respectively. Expression values from probes were used to calculate the PRKDC and APP fold changes and relative abundance reported in Tables 3 and 4.
Numbers in the boxes refer to the actual exon identification. (B) RT–PCR analysis of PRKDC in breast cell lines. The wild-type sequence (wt) and the short form
( 80) were amplified with sets of primers located in sequences adjacent to exons 79 and 81. (D) RT–PCR analysis of APP showing the relative amount of each
isoform in melanoma and brain tissues. C+ is a positive control made with equimolar amount of cloned isoforms, amplified with the same set of primers.
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Microarray platforms constitute the standard tools to assess
transcripts expression levels on a large scale. Alternative RNA
splicing hasbeen addressedinsomereports butnonedisplayed
the type of data required to validate the quantitative nature of
such platforms. This was the purpose of our study.
A ﬁrst study described the expression of novel or cassette
exons via the design of exon speciﬁc probes (46). Later, the
same group described the concept of tiling arrays in which
oligonucleotide probes are sequentially generated every 10 bp
along a predeﬁned genomic region. This allowed a more
precise deﬁnition of exon/intron boundaries by searching
for consensus splice sites within 20–30 bp sequences. Tiling
arrays at different resolutions have also been described to
monitor transcriptional activity in chromosomes 21 and 22
(9,47). Hu et al. (39) studied alternative splicing in the 30
end regions of 1600 rat genes by designing 20 different probes
per gene. Hybridizations performed with 10 normal tissues
predicted that 268 (17%) genes could be regulated via altern-
ative splicing. In another study, a global analysis of constitu-
tive RNA splicing in yeast has been performed via the design
of intron and exon/exon-junction-speciﬁc probes (40). This
study introduced the usage of exon junction spanning probes
interrogating sequences that are juxtaposed at the RNA level
but not at the genome level. The optimization and use of
junction probes to monitor exon skipping events were further
validated by Castle et al. (43) on the study of two genes (RB1
and ANXA7) and by Wang et al. (41) on another set of two
genes (CD44 and TPM2). Finally, an extensive analysis of
exon skipping events has been carried out by Johnson et al.
(42) using a microarray containing exon/exon junction probes
for over 10000 human genes that has been hybridized against
52 different biological samples. A prediction model was
applied to qualitatively detect differential splicing patterns
within the tested samples.
Our study describes a speciﬁc conﬁguration for monitoring
splice variant expression enabling the quantiﬁcation of the
absolute and relative splice variant expression levels when
comparing two samples. This conﬁguration requires a set of
junction and exon probes to characterize a splice event with
accuracy and sensitivity at the picomolar level. Alternate tran-
scripts can also be generated by mechanisms not related to
alternative splicing such as promoter usage and alternative
polyadenylation. Such events affecting the 50 and 30 extrem-
ities will be monitored by fewer probes as junction probes can
not be designed at these endings.
Probe design was optimized for sensitivity and speciﬁcity to
include homogenous predicted melting temperature, minimal
self-hybridization and minimal hairpintendencies. In addition,
we chose to use shorter oligonucleotides rather than 40mer or
above to avoid the potential hybridization of half of the junc-
tion probe to a single exon. The design of exon probes rarely
presents difﬁculties except when the exon size is limited. As
with conventional microarrays, care should be taken to avoid
cross-hybridization in particular with close homologs via
searching for sequence similarities with mRNAs and ESTs
populations. The location of the junction probes is restricted
to a speciﬁc region centered on the splice junction. This posi-
tional constraint may complicate probe design, making probe
composition not suitable to get the desired thermodynamic
parameters. However, junction probes can be designed with a
sequenceuptotwonucleotidesoff-centre,whichmaintainedthe
expected speciﬁcity (data not shown). In addition, shorter
probes could also be designed for problematic sequences
such as GC-rich regions. It should also be noted that, in the
case of the detection and quantiﬁcation of the long isoform,
uptothreeprobesaredesigned(Ex2,J1-2andJ2-3)whichallows
some ﬂexibility for the choice of the probe for quantiﬁcation.
Junction probes are expected to bring the expected speci-
ﬁcity in the case of closely related splice events For instance, it
has been recently reported that NAG insertions-deletions in
transcripts can occur due to splice acceptor sites displaying a
NAGNAG motif (48). Such three nucleotides insertion will
create a signiﬁcant mismatch between the probe and the target
that should guarantee the desired speciﬁcity of the junction
probes.
This microarray conﬁguration was initially validated
by performing spiking experiments where known amounts
of long and short recombinant RNA isoforms were co-
hybridized at various concentrations. Calculated fold changes
were found consistent with the expected values within ratios
ranging from 0.25 to 12. Additionally, we were able to quant-
ify relative amounts in each tested sample using simple alge-
bra. We further demonstrated that we could quantify speciﬁc
isoform expression deregulations within complex RNAs
derived from breast cell lines, brain and melanoma tissue
samples that were next conﬁrmed by RT–PCR. Importantly,
Table 4. Fold changes and relative abundance for deregulated isoforms in brain versus melanoma
Gene Isoform Fold changes Relative abundance
Brain/Melanoma Melanoma Brain
LF+SF (RE1)L F ( RE2)S F ( RJ) Reference Experimental
%L F %S F %L F %S F
PPIB Wild type (SF) 0.38 1.17 0.36 2.5 97.5 7.6 92.4
Intron 4 retention (LF)
APP
a Wild type + APP [-8] (LF) 1.39 0.94 3.81 84.3 15.7 57.0 43.0
Exon7- 8 skipping
(APP [-7/8] (SF)
MGC8721 Wild type (LF) 3.41 3.18 1.71 NA NA NA NA
Exon 2 skipping (SF)
Significantderegulationsarereportedinbold.RE2valuescorrespondtothemeanoffoldchangescalculatedwitheachLF-specificprobes(Ex2,J1-2andJ2-3).NA,not
applicable (see in text the limitations for the relative abundance determination).
aSee description of APP in Figure 4C.
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array conﬁguration by selecting the difﬁcult but frequent
setting in which isoforms generated via exon skipping are
expressed at lower levels concomitantly to the wild-type
isoform (cf. PRKDC). Instances in which alternative
cassette exons are exclusively expressed in given tissues are
indeed easy to quantify and could only rely on cassette
exonic probes.
Thismicroarrayplatformprovidesvariouslevelsofvaluable
information: at a very basic level, probes located in common
exons will provide expression values and deregulations for
given genes as observed with a regular microarray system.
The addition of junction probes and probes speciﬁc for altern-
ative events gives access to isoform deregulation between
two zsamples. Finally, when two isoforms with a signiﬁcant
deregulation are present in the samples to be compared, we
havedevelopedacalculationmethodthatwillallowquantiﬁca-
tion of the relative ratios between the isoforms in each sample.
We are facing the same limitations associated with any
microarray platform. Thus, probes with expression values
below the sensitivity of the platform will not be appropriate.
In addition,determination of the isoform relative abundance in
each sample is dependent of the fold change values calculated
for RE1, RE2 and RJ. Inaccurate relative abundance determina-
tion can occur when: (i) RE1   RE2 (the LF proportion in each
sample is close to 100%), (ii) RE1   RJ (the SF proportion in
each sample is close to 100%) and (iii) RE1   RE2   RJ (the SF
to LF ratios are similar in each sample). Additionally, when
RE1, RE2 and RJ fall within 0.6 and 1.8, we consider no sig-
niﬁcant isoform deregulation between the samples and calcu-
lation of the relative isoform abundance may be biased.
In addition, like any microarray, we detect and quantify
targets that are complementary to probes displayed on the
array, i.e. splice events and not full-length spliced transcripts.
Any splicing event can be present in more than one isoform
and one isoform can include more than one splice event. This
was exempliﬁed in the APP isoforms that were studied in the
brain and melanoma samples.
Today’s commercial microarray platforms proposed for
global human genome expression are inappropriate to system-
atically detect splice variants. Probe sets are often 30 biased
and are not designed according to the types of conﬁguration
described in this study. In addition, data analysis is performed
in such a way that multiple measurements are used to deﬁne a
consensual behavior amongst the probes, remove outliers and
produce a unique ﬁgure associated with the expression level of
the gene in a given sample. The APP isoforms deregulations
described in this study would have been missed by such
platforms.
The new type of microarrays described here will certainly
provide the necessary tools to obtain a more comprehensive
and accurate picture of gene expression, help decipher the
regulation networks of alternative RNA splicing and open
the way to innovative and better proﬁled therapeutics. We
are currently evaluating this microarray conﬁguration for the
detection and the quantiﬁcation of splice events from
the GPCR gene family.
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